Abstract
In the present study, SGC-7901/DDP cells were treated with different concentrations of parthenolide (PN) (2.5-15 µmol/l), cisplatin (DDP) (1.25-15 µg/ml) and PN+DDP. The proliferation inhibition rates were measured using an MTT assay, and the synergies of PN and DDP were analyzed. The effect of PN and DDP on SGC-7901/DDP cell proliferation demonstrated a time- and concentration-dependent association, and a synergy between PN and DDP was identified. DAPI staining and flow cytometry results indicated that 15 µmol/l PN significantly induced SGC-7901/DDP apoptosis and G1phase arrest compared with the untreated control group. Western blotting analysis results indicated that among the apoptosis-associated proteins, there were dose-dependent increases in the protein expression of apoptosis regulator BAX, cellular tumor antigen p53, cleaved caspase-3 and cleaved capase-9, and decreases in apoptosis regulator Bcl-2 and Bcl-xL protein expression levels. Among the cell cycle-associated proteins, cyclin D1 expression was significantly decreased, cyclin-dependent kinase inhibitor 1 expression was significantly increased, and signal transducer and activator of transcription 3 (STAT3) activation was inhibited. Scratch and Transwell assay resu...Continue Reading
References
Apr 14, 2005·Molecular Cancer Therapeutics·Michele T Yip-SchneiderC Max Schmidt
Aug 4, 2005·Acta Biochimica Et Biophysica Sinica·Xiao-Yong LeiDuan-Fang Liao
Oct 20, 2006·Apoptosis : an International Journal on Programmed Cell Death·Wei WangYasuhisa Shinomura
Nov 23, 2006·Trends in Molecular Medicine·Benjamin BarréOlivier Coqueret
Jan 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuki KishidaAkira Myoui
Jul 1, 2008·Cancer Chemotherapy and Pharmacology·Zhenfeng DuanMichael V Seiden
Feb 11, 2009·The Prostate·Brian T KawasakiWilliam L Farrar
Jan 1, 2008·Journal of Oncology·Valentina CalderaDavide Schiffer
Feb 13, 2010·The Journal of Obstetrics and Gynaecology Research·Hao Min, Zhao Wei-hong
Mar 9, 2010·The Prostate·Rajasubramaniam ShanmugamChristopher J Sweeney
Jun 29, 2010·Current Cancer Drug Targets·Z W GaoC B Guo
Jul 2, 2010·British Journal of Pharmacology·M CzyzM Wozniak
Aug 12, 2010·Journal of Experimental & Clinical Cancer Research : CR·Jun-Wei LiuDong-Sheng Huang
Aug 13, 2010·British Journal of Haematology·Yun DaiSteven Grant
Mar 18, 2011·Journal of Cellular Physiology·Daniela CarlisiGiovanni Tesoriere
Mar 23, 2011·Leukemia & Lymphoma·Ellen J GunnJulia Kirshner
Mar 24, 2011·The Cancer Journal·Valentina FodaleEmanuel Petricoin
Aug 11, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Guang Cheng, Liping Xie
Sep 13, 2011·Oncogene·P YueJ Turkson
Nov 23, 2011·Cancer Letters·Shuling HuangXiaoping Zou
Apr 26, 2012·Molecular Cancer Therapeutics·Shinji KohsakaShinya Tanaka
May 24, 2012·Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract·Bryan K HolcombC Max Schmidt
Oct 6, 2012·Cancer Prevention Research·Akram GhantousNadine Darwiche
Apr 9, 2013·Future Oncology·Dajun LiuYan Li
Nov 10, 2013·Current Cancer Drug Targets·Jung M SongFekadu Kassie
Oct 8, 2014·Pharmaceutical Biology·Anees A Al-FatlawiAyaz Ahmad
May 20, 2015·Oncogene·N D PeyserJ R Grandis
Citations
Jun 18, 2020·Biology·Milad AshrafizadehReza Mohammadinejad
Sep 3, 2020·Cancers·Ping-Lian YangLi-Yan Xu
Jun 6, 2019·Frontiers in Pharmacology·Mona DawoodThomas Efferth
Aug 3, 2019·International Journal of Molecular Sciences·Sabino RussiVitalba Ruggieri
Nov 30, 2019·Oxidative Medicine and Cellular Longevity·Elena ButturiniSofia Mariotto
Aug 23, 2020·Pharmaceuticals·Malgorzata Sztiller-Sikorska, Malgorzata Czyz
Jan 25, 2020·Journal of Medicinal Chemistry·Yahui DingQuan Zhang
Dec 9, 2020·Journal of Medicinal Chemistry·Yulin Ren, A Douglas Kinghorn